Literature DB >> 27466425

HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.

Rebecca Rose1, Susanna L Lamers1, David J Nolan2, Ekaterina Maidji3, N R Faria4, Oliver G Pybus4, James J Dollar5, Samuel A Maruniak5, Andrew C McAvoy5, Marco Salemi5, Cheryl A Stoddart3, Elyse J Singer6, Michael S McGrath7.   

Abstract

UNLABELLED: While combined antiretroviral therapy (cART) can result in undetectable plasma viral loads, it does not eradicate HIV infection. Furthermore, HIV-infected individuals while on cART remain at an increased risk of developing serious comorbidities, such as cancer, neurological disease, and atherosclerosis, suggesting that during cART, tissue-based HIV may contribute to such pathologies. We obtained DNA and RNA env, nef, and pol sequences using single-genome sequencing from postmortem tissues of three HIV(+) cART-treated (cART(+)) individuals with undetectable viral load and metastatic cancer at death and performed time-scaled Bayesian evolutionary analyses. We used a sensitive in situ hybridization technique to visualize HIV gag-pol mRNA transcripts in cerebellum and lymph node tissues from one patient. Tissue-associated virus evolved at similar rates in cART(+) and cART-naive (cART(-)) patients. Phylogenetic trees were characterized by two distinct features: (i) branching patterns consistent with constant viral evolution and dispersal among tissues and (ii) very recently derived clades containing both DNA and RNA sequences from multiple tissues. Rapid expansion of virus near death corresponded to wide-spread metastasis. HIV RNA(+) cells clustered in cerebellum tissue but were dispersed in lymph node tissue, mirroring the evolutionary patterns observed for that patient. Activated, infiltrating macrophages were associated with HIV RNA. Our data provide evidence that tissues serve as a sanctuary for wild-type HIV during cART and suggest the importance of macrophages as an alternative reservoir and mechanism of virus spread. IMPORTANCE: Combined antiretroviral therapy (cART) reduces plasma HIV to undetectable levels; however, removal of cART results in plasma HIV rebound, thus highlighting its inability to entirely rid the body of infection. Additionally, HIV-infected individuals on cART remain at high risk of serious diseases, which suggests a contribution from residual HIV. In this study, we isolated and sequenced HIV from postmortem tissues from three HIV(+) cART(+) individuals who died with metastatic cancer and had no detectable plasma viral load. Using high-resolution evolutionary analyses, we found that tissue-based HIV continues to replicate, evolve, and migrate among tissues during cART. Furthermore, cancer onset and metastasis coincided with increased HIV expansion, suggesting a linked mechanism. HIV-expressing cells were associated with tissue macrophages, a target of HIV infection. Our results suggest the importance of tissues, and macrophages in particular, as a target for novel anti-HIV therapies.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27466425      PMCID: PMC5044847          DOI: 10.1128/JVI.00684-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Macrophages archive HIV-1 virions for dissemination in trans.

Authors:  Natalia Sharova; Catherine Swingler; Mark Sharkey; Mario Stevenson
Journal:  EMBO J       Date:  2005-05-26       Impact factor: 11.598

Review 3.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

4.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 5.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

6.  Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.

Authors:  Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

7.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.

Authors:  Susanna L Lamers; Rebecca Rose; Ekaterina Maidji; Melissa Agsalda-Garcia; David J Nolan; Gary B Fogel; Marco Salemi; Debra L Garcia; Paige Bracci; William Yong; Deborah Commins; Jonathan Said; Negar Khanlou; Charles H Hinkin; Miguel Valdes Sueiras; Glenn Mathisen; Suzanne Donovan; Bruce Shiramizu; Cheryl A Stoddart; Michael S McGrath; Elyse J Singer
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

Review 8.  Macrophage polarization at the crossroad between HIV-1 infection and cancer development.

Authors:  Massimo Alfano; Francesca Graziano; Luca Genovese; Guido Poli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06       Impact factor: 8.311

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

Review 10.  Interferon-alpha, immune activation and immune dysfunction in treated HIV infection.

Authors:  Lilian Cha; Cassandra M Berry; David Nolan; Allison Castley; Sonia Fernandez; Martyn A French
Journal:  Clin Transl Immunology       Date:  2014-02-28
View more
  25 in total

1.  NLRP3 inflammasome induces CD4+ T cell loss in chronically HIV-1-infected patients.

Authors:  Chao Zhang; Jin-Wen Song; Hui-Huang Huang; Xing Fan; Lei Huang; Jian-Ning Deng; Bo Tu; Kun Wang; Jing Li; Ming-Ju Zhou; Cui-Xian Yang; Qi-Wen Zhao; Tao Yang; Li-Feng Wang; Ji-Yuan Zhang; Ruo-Nan Xu; Yan-Mei Jiao; Ming Shi; Feng Shao; Rafick-Pierre Sékaly; Fu-Sheng Wang
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 2.  Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.

Authors:  Rebecca Rose; David J Nolan; Ekaterina Maidji; Cheryl A Stoddart; Elyse J Singer; Susanna L Lamers; Michael S McGrath
Journal:  AIDS Res Hum Retroviruses       Date:  2017-08-07       Impact factor: 2.205

3.  Predicted coreceptor usage at end-stage HIV disease in tissues derived from subjects on antiretroviral therapy with an undetectable plasma viral load.

Authors:  S L Lamers; G B Fogel; E S Liu; D J Nolan; M Salemi; A E Barbier; R Rose; E J Singer; M S McGrath
Journal:  Infect Genet Evol       Date:  2017-04-06       Impact factor: 3.342

Review 4.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

5.  HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.

Authors:  Susanna L Lamers; Rebecca Rose; Ekaterina Maidji; Melissa Agsalda-Garcia; David J Nolan; Gary B Fogel; Marco Salemi; Debra L Garcia; Paige Bracci; William Yong; Deborah Commins; Jonathan Said; Negar Khanlou; Charles H Hinkin; Miguel Valdes Sueiras; Glenn Mathisen; Suzanne Donovan; Bruce Shiramizu; Cheryl A Stoddart; Michael S McGrath; Elyse J Singer
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

6.  Brain-specific HIV Nef identified in multiple patients with neurological disease.

Authors:  Susanna L Lamers; Gary B Fogel; Enoch S Liu; Andrew E Barbier; Christopher W Rodriguez; Elyse J Singer; David J Nolan; Rebecca Rose; Michael S McGrath
Journal:  J Neurovirol       Date:  2017-10-23       Impact factor: 2.643

7.  HIV persists throughout deep tissues with repopulation from multiple anatomical sources.

Authors:  Antoine Chaillon; Sara Gianella; Simon Dellicour; Stephen A Rawlings; Timothy E Schlub; Michelli Faria De Oliveira; Caroline Ignacio; Magali Porrachia; Bram Vrancken; Davey M Smith
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 8.  The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy.

Authors:  Erin M B Scholz; Angela D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2021-02-28       Impact factor: 6.875

9.  Development of a Novel In Vitro Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription.

Authors:  Anna C Hearps; Anthony Jaworowski; Michelle E Wong; Chad J Johnson
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

10.  A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.

Authors:  Erin M B Scholz; Yanguang Cao; Angela D M Kashuba
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.